

Christoph B Olivier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3863497/publications.pdf>

Version: 2024-02-01

30
papers

417
citations

933264

10
h-index

752573

20
g-index

31
all docs

31
docs citations

31
times ranked

825
citing authors

#	ARTICLE	IF	CITATIONS
1	Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 712-721.	1.0	8
2	Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 101-108.	0.5	9
3	Platelet Bone Morphogenetic Protein-4 Mediates Vascular Inflammation and Neointima Formation after Arterial Injury. <i>Cells</i> , 2021, 10, 2027.	1.8	10
4	P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. <i>Scientific Reports</i> , 2021, 11, 17459.	1.6	14
5	Medical history of coronary artery disease and time to electrocardiogram in the emergency department: a real-life, single-center, retrospective analysis. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 480.	0.7	0
6	Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. <i>Journal of Pharmacy Practice</i> , 2020, 33, 647-653.	0.5	17
7	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. <i>Journal of Vascular Access</i> , 2020, 21, 467-474.	0.5	1
8	Evaluation of Serum Serotonin as a Biomarker for Myocardial Infarction and Ischemia/Reperfusion Injury. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6379.	1.3	2
9	Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 414.	1.2	3
10	Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007604.	1.4	10
11	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	1.4	10
12	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	0.7	4
13	Anticoagulation and anaemia: old opponents from the era of VKA?. <i>European Heart Journal</i> , 2019, 40, 3791-3792.	1.0	4
14	Is Bleeding Always Bad?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1529-1531.	1.2	1
15	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	3.0	26
16	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 251-258.	1.0	3
17	Moderate ischemic mitral regurgitation: coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve. <i>Journal of Cardiovascular Surgery</i> , 2018, 59, 830-835.	0.3	3
18	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	0.8	10

#	ARTICLE	IF	CITATIONS
19	The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count. PLoS ONE, 2016, 11, e0149053.	1.1	7
20	MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. Vascular Pharmacology, 2016, 84, 67-73.	1.0	8
21	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. Journal of Thrombosis and Thrombolysis, 2016, 42, 558-565.	1.0	3
22	TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thrombosis Research, 2016, 138, 63-68.	0.8	31
23	Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel. Journal of Thrombosis and Thrombolysis, 2016, 42, 84-89.	1.0	6
24	Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. Journal of Thrombosis and Thrombolysis, 2016, 42, 161-166.	1.0	21
25	Role of microparticles in endothelial dysfunction and arterial hypertension. World Journal of Cardiology, 2014, 6, 1135.	0.5	47
26	A high ratio of ADP to TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. Clinical Research in Cardiology, 2014, 103, 968-975.	1.5	10
27	Triple antithrombotic therapy in cardiac patients: more questions than answers. European Heart Journal, 2014, 35, 216-223.	1.0	32
28	Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thrombosis and Haemostasis, 2014, 112, 266-272.	1.8	26
29	Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clinical Research in Cardiology, 2011, 100, 765-771.	1.5	29
30	Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Research in Cardiology, 2010, 105, 379-387.	2.5	62